117 related articles for article (PubMed ID: 12821070)
1. [Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations].
Cabaret AS; Levêque J; Dugast C; Blanchot J; Grall JY
Gynecol Obstet Fertil; 2003 Apr; 31(4):370-7. PubMed ID: 12821070
[TBL] [Abstract][Full Text] [Related]
2. [Problems raised by the gynaecologic management of women with BRCA 1 & 2 mutations.Gynécol Obstét Fertil 2003;31:370-377].
Stoppa-Lyonnet D
Gynecol Obstet Fertil; 2003 Oct; 31(10):888-9; author reply 889. PubMed ID: 14642951
[No Abstract] [Full Text] [Related]
3. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
4. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
5. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.
Schrag D; Kuntz KM; Garber JE; Weeks JC
JAMA; 2000 Feb; 283(5):617-24. PubMed ID: 10665701
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?
Kotsopoulos J; Narod SA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):199-200. PubMed ID: 29308680
[No Abstract] [Full Text] [Related]
7. The Preventive Intervention of Hereditary Breast Cancer.
Cao A; Huang L; Shao Z
Adv Exp Med Biol; 2017; 1026():41-57. PubMed ID: 29282679
[TBL] [Abstract][Full Text] [Related]
8. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Guidozzi F
Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
[TBL] [Abstract][Full Text] [Related]
9. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
10. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
11. Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.
Grann VR; Jacobson JS; Thomason D; Hershman D; Heitjan DF; Neugut AI
J Clin Oncol; 2002 May; 20(10):2520-9. PubMed ID: 12011131
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
Salyer C; Kobelka C; Barrie A; Weintraub MR; Powell CB
Gynecol Oncol; 2019 Aug; 154(2):374-378. PubMed ID: 31160070
[TBL] [Abstract][Full Text] [Related]
13. [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
Bit-Sava EM; Belogurova MB; Imianitov EN; Balandov SG; Korniushin OV; Borisov MK
Vopr Onkol; 2013; 59(2):5-11. PubMed ID: 23814843
[No Abstract] [Full Text] [Related]
14. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review.
Bermejo-Pérez MJ; Márquez-Calderón S; Llanos-Méndez A
Int J Cancer; 2007 Jul; 121(2):225-31. PubMed ID: 17471565
[TBL] [Abstract][Full Text] [Related]
16. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
Giannakeas V; Narod SA
Breast Cancer Res Treat; 2018 Jan; 167(1):263-267. PubMed ID: 28914396
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Risk Reduction Decisions of the BRCA-Positive Patient: An Observational Study at a Single Institution.
Johns D; Agarwal J; Anderson L; Ying J; Kohlmann W
J Womens Health (Larchmt); 2017 Jun; 26(6):702-706. PubMed ID: 27922795
[TBL] [Abstract][Full Text] [Related]
18. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
20. Management options after prophylactic surgeries in women with BRCA mutations: a review.
Allain DC; Sweet K; Agnese DM
Cancer Control; 2007 Oct; 14(4):330-7. PubMed ID: 17914333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
